SCHEMBL29014071

SCHEMBL29014071

O=C(On1cc2cc(Br)ccc2n1)N1CCCCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 10/20 0.53
RAB9A P51151 10/20 0.53
SMN1; SMN2 Q16637 6/20 0.53
MAPT P10636 4/20 0.53
LMNA P02545 2/20 0.53
ATM Q13315 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
ALDH1A1 P00352 6/20 0.42
HTT P42858 3/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HPGD P15428 6/20 0.38
NPSR1 Q6W5P4 1/20 0.38
POLB P06746 1/20 0.38
HDAC8 Q9BY41 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21612951 0.78 RAB9A (0.42) NPC1RAB9ASMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL28633833 0.71 HPGD (0.39) NPC1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL5648948 0.71 SMN1; SMN2 (0.41) NPC1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL5649629 0.71 ALDH1A1 (0.45) NPC1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL829826 0.70 SMN1; SMN2 (1.00) NPC1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL18093695 0.68 NPC1 (0.55) NPC1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL21612900 0.67 RAB9A (0.39) NPC1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL25296039 0.65 HDAC8 (0.47) NPC1RAB9AMAPTATMTDP1
SCHEMBL830131 0.65 SMN1; SMN2 (0.72) NPC1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL30886888 0.64 HDAC8 (0.39) NPC1RAB9ASMN1; SMN2MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116249554-A Compounds and their use in the treatment of cancer 阿斯利康(瑞典)有限公司 2023-06-09 CN disclosed